Antiangiogenic	O
and	O
antitumor	B-Cancer
effects	O
of	O
a	O
protein	O
kinase	O
Cbeta	O
inhibitor	O
in	O
human	O
breast	B-Cancer
cancer	I-Cancer
and	O
ovarian	B-Cancer
cancer	I-Cancer
xenografts	I-Cancer
.	O

In	O
cell	B-Cell
culture	I-Cell
,	O
the	O
compound	O
317615	O
2HCl	O
,	O
a	O
potent	O
inhibitor	O
of	O
VEGF	O
-	O
stimulated	O
HUVEC	B-Cell
proliferation	O
,	O
was	O
not	O
very	O
effective	O
against	O
MX	B-Cell
-	I-Cell
1	I-Cell
breast	I-Cell
cancer	I-Cell
cells	I-Cell
(	O
IC50	O
=	O
8	O
.	O
1	O
microM	O
)	O
or	O
SKOV	B-Cell
-	I-Cell
3	I-Cell
ovarian	I-Cell
carcinoma	I-Cell
cells	I-Cell
(	O
IC50	O
=	O
9	O
.	O
5	O
microM	O
)	O
.	O

Exposure	O
to	O
combinations	O
of	O
paclitaxel	O
or	O
carboplatin	O
and	O
317615	O
x	O
2HCl	O
with	O
MX	B-Cell
-	I-Cell
1	I-Cell
cells	I-Cell
in	O
culture	O
resulted	O
in	O
cell	B-Cell
survival	O
that	O
reflected	O
primarily	O
additivity	O
of	O
the	O
two	O
agents	O
.	O

Exposure	O
of	O
SKOV	B-Cell
-	I-Cell
3	I-Cell
cells	I-Cell
to	O
paclitaxel	O
or	O
carboplatin	O
along	O
with	O
317615	O
2HCl	O
resulted	O
in	O
cell	B-Cell
survivals	O
that	O
reflected	O
additivity	O
of	O
317615	O
x	O
2HCl	O
with	O
paclitaxel	O
and	O
greater	O
-	O
than	O
-	O
additive	O
cytotoxicity	O
with	O
carboplatin	O
.	O

Administration	O
of	O
317615	O
x	O
2HCI	O
orally	B-Organism_subdivision
twice	O
daily	O
to	O
nude	O
mice	O
bearing	O
subcutaneous	B-Cancer
MX	I-Cancer
-	I-Cancer
1	I-Cancer
tumors	I-Cancer
or	O
SKOV	B-Cancer
-	I-Cancer
3	I-Cancer
tumors	I-Cancer
resulted	O
in	O
a	O
decreased	O
number	O
of	O
intratumoral	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
as	O
determined	O
by	O
CD31	O
and	O
CD105	O
staining	O
with	O
decreases	O
of	O
35	O
%	O
and	O
43	O
%	O
in	O
MX	B-Cancer
-	I-Cancer
1	I-Cancer
tumors	I-Cancer
and	O
60	O
%	O
and	O
75	O
%	O
in	O
SKOV	B-Cancer
-	I-Cancer
3	I-Cancer
tumors	I-Cancer
,	O
respectively	O
.	O

317615	O
x	O
2HCl	O
was	O
an	O
active	O
antitumor	B-Cancer
agent	O
against	O
the	O
MX	B-Cancer
-	I-Cancer
1	I-Cancer
xenograft	I-Cancer
and	O
increased	O
the	O
tumor	B-Cancer
growth	O
delay	O
produced	O
by	O
paclitaxel	O
by	O
1	O
.	O
7	O
-	O
fold	O
and	O
the	O
tumor	B-Cancer
growth	O
delay	O
produced	O
by	O
carboplatin	O
by	O
3	O
.	O
8	O
-	O
fold	O
.	O

Administration	O
of	O
317615	O
x	O
2HCl	O
also	O
increased	O
the	O
tumor	B-Cancer
growth	O
delay	O
produced	O
by	O
fractionated	O
radiation	O
therapy	O
in	O
the	O
MX	B-Cancer
-	I-Cancer
1	I-Cancer
tumor	I-Cancer
.	O

Treatment	O
with	O
317615	O
x	O
2HCl	O
alone	O
increased	O
the	O
lifespan	O
of	O
animals	O
bearing	O
intraperitoneal	B-Cancer
SKOV	I-Cancer
-	I-Cancer
3	I-Cancer
xenografts	I-Cancer
by	O
1	O
.	O
9	O
fold	O
compared	O
with	O
untreated	O
control	O
animals	O
.	O

The	O
combination	O
of	O
paclitaxel	O
and	O
317615	O
x	O
2HCl	O
resulted	O
in	O
100	O
%	O
120	O
-	O
day	O
survival	O
of	O
SKOV	B-Cancer
-	I-Cancer
3	I-Cancer
bearing	O
animals	O
.	O

Administration	O
of	O
317615	O
x	O
2HCl	O
along	O
with	O
carboplatin	O
to	O
animals	O
bearing	O
the	O
SKOV	B-Cancer
-	I-Cancer
3	I-Cancer
tumor	I-Cancer
produced	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
lifespan	O
compared	O
with	O
carboplatin	O
alone	O
.	O

317615	O
x	O
2HCl	O
is	O
a	O
promising	O
new	O
antiangiogenic	O
agent	O
that	O
is	O
in	O
early	O
phase	O
clinical	O
testing	O
.	O

